Want to see NOVT full AI Analyst Report?
NOVT Stock Chart & Stats
$141.54
-$0.74(-0.52%)
At close: 4:00 PM EDT
$141.54
-$0.74(-0.52%)
Day’s Range― - ―
52-Week Range$98.27 - $176.38
Previous Close$140.8
Volume290.87K
Average Volume (3M)529.02K
Market Cap
$5.49B
Enterprise Value$6.22K
Total Cash (Recent Filing)$718.65M
Total Debt (Recent Filing)$282.82M
Price to Earnings (P/E)91.3
Beta1.73
Next Earnings
Nov 10, 2026EPS Estimate
0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding37,817,770
10 Day Avg. Volume382,665
30 Day Avg. Volume529,021
Financial Highlights & Ratios
PEG Ratio-4.65
Price to Book (P/B)3.31
Price to Sales (P/S)4.44
P/FCF Ratio89.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$194.00Price Target Upside37.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.59
Revenue Forecast (FY)$1.05B
Bulls Say, Bears Say
Bulls Say
Raised Growth And Earnings OutlookHigher guidance reflects broad-based organic growth, acquisition contribution and improving operating performance. Continued revenue expansion and expected EBITDA growth provide a durable foundation for earnings over the next several quarters.
Strong Cash GenerationRobust cash conversion improves funding flexibility for investment, integration and debt reduction. The rebound from 2025 also supports earnings quality, although historical volatility means working-capital timing remains important.
New-product And Bookings MomentumStrong innovation output, bookings and backlog indicate customer adoption and future demand visibility. Design wins and rising vitality-index sales can deepen OEM relationships and support differentiated, higher-value content over time.
Bears Say
Persistent Profitability PressureLower operating and medical margins show that revenue growth is not yet translating proportionally into profit. Mix toward lower-margin products, transformation costs and site rationalization could constrain margin recovery over the next several quarters.
Higher Acquisition-related LeverageAcquisition financing increases interest obligations and reduces financial flexibility until synergies and cash flow materialize. Integration execution and the potential $250M milestone payment could prolong leverage pressure if performance falls short.
Weakness In Precision Medicine And Life SciencesLimited growth in these businesses creates a drag on organic expansion and diversification. Commoditization and a recovery targeted only for late 2027 suggest pressure may persist beyond the immediate reporting cycle.
NOVT FAQ
What was Novanta’s price range in the past 12 months?
Novanta lowest stock price was $98.27 and its highest was $176.38 in the past 12 months.
What is Novanta’s market cap?
Novanta’s market cap is $5.49B.
When is Novanta’s upcoming earnings report date?
Novanta’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Novanta’s earnings last quarter?
Novanta released its earnings results on Aug 05, 2026. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.06.
Is Novanta overvalued?
According to Wall Street analysts Novanta’s price is currently Undervalued.
Does Novanta pay dividends?
Novanta does not currently pay dividends.
What is Novanta’s EPS estimate?
Novanta’s EPS estimate is 0.97.
How many shares outstanding does Novanta have?
Novanta has 37,817,770 shares outstanding.
What happened to Novanta’s price movement after its last earnings report?
Novanta reported an EPS of $0.89 in its last earnings report, beating expectations of $0.83. Following the earnings report the stock price went up 6.661%.
Which hedge fund is a major shareholder of Novanta?
Currently, no hedge funds are holding shares in NOVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novanta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$194.00 (37.06% Upside)
$194.00 (37.06% Upside)
Blogger Sentiment
Neutral
NOVT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 250.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.59%
Trailing 12-Months
Company Description
Novanta
Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors. Within its Photonics division, Novanta provides a suite of laser-driven technologies. These encompass systems for laser scanning, beam manipulation, and various laser types such as CO2, solid-state, ultrafast, and optical light engines. Their applications span critical areas like industrial manufacturing, precision measurement (metrology), advanced imaging in healthcare and biological research, DNA sequencing, and specialized medical laser treatments. The Vision segment delivers an array of medical-grade innovations. This portfolio comprises instruments like medical insufflators, pumps, and their associated consumables, alongside comprehensive visualization tools. It also features wireless communication systems, video recording devices, and integration platforms designed for operating theaters. Further offerings include optical data acquisition, machine vision systems, radio frequency identification (RFID) solutions, thermal recording devices, spectrometry equipment, and integrated touchscreen displays. Furthermore, the Precision Motion division specializes in supplying components such as optical and inductive encoders, high-precision motors, servo drives, and complete motion control systems. This segment also delivers integrated stepper motors, sophisticated robotic end-effectors, air bearings, and air bearing spindles. Novanta distributes its extensive product lines through various channels, including its dedicated direct sales team, value-added resellers, distribution partners, and system integrators. These offerings are available under well-known brand names such as Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind. Founded in 1968, the company operated as GSI Group, Inc. until its rebranding to Novanta Inc. in May 2016. Its corporate headquarters are located in Bedford, Massachusetts.
NOVT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was positive: management reported broad-based organic growth, margin expansion, strong cash generation, significant new product momentum, and closed an accretive strategic acquisition (Riverpoint) that raises guidance. There are manageable near-term headwinds — lower medical segment margins from mix and transformation costs, supply-chain/tariff pressures, integration and restructuring expenses, and a temporary rise in gross leverage from acquisition financing — but management provided clear plans and guidance to offset these over time. The highlights materially outweigh the lowlights.View all NOVT earnings summariesNOVT Stock 12 Month Forecast
Average Price Target
$194.00
▲(37.06% Upside)
Technical Analysis
Ownership Overview
0.71% Insiders
43.47% Mutual Funds
23.18% Other Institutional Investors
4.34% Public Companies and
Individual Investors










